Skip to Search
Skip to Main Content
Skip to Footer
Google Translate
Select language
English
French
German
Italian
Portuguese
Spanish
User Login
Username
*
Password
*
Administration Login
×
Google Translate
Select language
English
French
German
Italian
Portuguese
Spanish
RESEARCH
Powered by EBSCO
Menu
Site Search
Search Options
Curated Discovery
More Research
Publication Finder
Google Scholar
All
COVID-19 Related Subjects Only
Back to COVID-19 Information Portal
Open Access Resources
RSS Feed
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
Prostate Cancer in Transgender Women in the Veterans Affairs Health
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency
FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency
FDA Approves Once-Weekly Sogroya for the Treatment of Children Living with Growth Hormone Deficiency
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
×